CD30 is a transmembrane glycoprotein receptor that is a member of the tumor necrosis actor receptor family,[17] and it is noted in both reactive and neoplastic infiltrates.[18] The phenotype of CD4+/CD8+ is a rare subtype of SPTCL as reported previously.[15] Five in 9 cases show the CD4+/CD8+ phenotype, and no significant difference in clinicopathologic features was found when compared to the phenotype of CD4−/CD8+.[7]In another study, the proliferation marker Ki-67 staining ≥60% was observed in 72%–80% of patients,[5,7]which was similar to our case. Here, CD4 is linked to subcutaneous panniculitis-like T-cell lymphoma.